Welcome to our dedicated page for Cybin SEC filings (Ticker: CYBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CYBN SEC filings page on Stock Titan aggregates Cybin Inc.’s regulatory disclosures as a foreign issuer, giving investors structured access to the company’s official documents. Cybin files with the U.S. Securities and Exchange Commission primarily on Form 40-F and Form 6-K, and also uses Form 25 for listing changes. These filings are central to understanding the company’s clinical-stage neuropsychiatry business, its capital structure, and its transition between stock exchanges.
Form 6-K submissions for Cybin typically include interim consolidated financial statements, management’s discussion and analysis, certifications of interim filings, and news releases. Many 6-Ks also incorporate material change reports, equity distribution agreements, and prospectus-related documents by reference into Cybin’s registration statements on Form F-10. For a company developing drug candidates such as CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, these filings provide context on how clinical programs are funded and governed.
The filings page also features Cybin’s Form 25, which notifies the SEC of the voluntary removal of its common shares from listing and registration on the NYSE American. This document confirms that the company has complied with the exchange’s rules and the requirements for voluntary withdrawal, and it aligns with Cybin’s news release describing its plan to transfer its U.S. listing to the Nasdaq Global Market and to change its trading symbol from CYBN to HELP.
On Stock Titan, each new Cybin filing from EDGAR is captured and presented with AI-powered summaries that explain the purpose and key points of documents such as 6-Ks, F-10 registration statements, and the Form 25 delisting notice. This helps readers quickly understand how Cybin reports its financial results, documents material changes, and manages its listing status, while still allowing direct access to the underlying SEC filings for detailed review.
CYBIN INC. filed a Form D for a new, Regulation D exempt offering under Rule 506(b) to register up to $120,070 USD in potential proceeds, which represents the maximum amount potentially received from the exercise of stock options. No proceeds have been sold yet and total remaining to be sold is $120,070 USD. The securities consist primarily of stock options exercisable at CAD$11.00 per share that vest in eight quarterly tranches beginning September 30, 2025. The offering is intended to last more than one year. No sales commissions or finders’ fees were disclosed and no proceeds are allocated to named executives or directors. One investor is reported and one non-accredited investor has participated.
CYBIN Inc. discloses a shelf prospectus supplement highlighting clinical-stage psychedelic drug development and material risks. The filing emphasizes that psilocin is not approved by Health Canada or the U.S. FDA and that the company does not handle controlled substances except within licensed laboratory or clinical trial settings. The company warns of substantial quarter-to-quarter losses and uncertainty about its ability to raise additional funding. Key development milestones include topline efficacy readout from the first Phase 3 study (APPROACH) for deuterated psilocin (CYB003), progression of two additional Phase 3 studies (EMBRACE, EXTEND), a Phase 2 GAD topline readout for deuterated DMT (CYB004), and advancing a drug development candidate from the phenethylamine/tryptamine program (CYB005). The filing notes reliance on third parties for trials and manufacturing and risk from changing laws across multiple jurisdictions.
CYBIN Inc. discloses financing and operational risks and outlines clinical development milestones across three programs. The company warns of uncertainty in raising additional funds, potential continued substantial losses, pandemic-related risks, regulatory constraints around psychedelic substances, and reliance on key personnel. It states it does not currently handle controlled substances outside approved laboratory or clinical settings and would need licenses and approvals to do so directly.
The filing lists near-term development objectives: topline efficacy readout from the first Phase 3 study (APPROACH) and progression of two additional Phase 3 studies (EMBRACE, EXTEND) for deuterated psilocin (CYB003); completion and topline data from a Phase 2 GAD study for deuterated DMT (CYB004); delivery of a drug development candidate for the phenethylamine and tryptamine derivatives program (CYB005); and use of proceeds for working capital and general corporate purposes.
CYBIN Inc. is offering securities via a secondary prospectus supplement and outlines risks, regulatory constraints and clinical-development milestones. The document emphasizes that the company currently does not handle controlled or restricted substances under Canadian or U.S. law and only works with psychedelic compounds within approved laboratory and clinical-trial frameworks or via third parties where required. Key near-term development objectives include topline efficacy readout from the first Phase 3 study (APPROACH) and progression of two additional Phase 3 studies (EMBRACE, EXTEND) for the deuterated psilocin program (CYB003), completion and topline data from a Phase 2 GAD study for deuterated DMT (CYB004), and delivery of a drug development candidate for the phenethylamine/tryptamine derivatives program (CYB005). The prospectus warns of continuing substantial losses, pandemic risks, potential clinical-trial delays, reliance on key personnel, and regulatory changes across multiple jurisdictions.
CYBIN Inc. discloses risks around a proposed secondary offering, including uncertainty in raising additional funding and continued substantial losses. The company emphasizes regulatory constraints on psychedelic substances in key jurisdictions and states it currently does not handle controlled substances outside approved laboratory or clinical trial settings. Clinical development milestones are outlined: Phase 3 topline readout for deuterated psilocin (CYB003) and progression of two additional Phase 3 studies, a Phase 2 completion and topline readout for deuterated DMT (CYB004), and delivery of a drug development candidate from the CYB005 program. Proceeds are intended for working capital and general corporate purposes.